Market Overview:
The global amebiasis therapeutics market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of amebiasis and rising demand for effective and safe drugs for its treatment. Based on type, the global amebiasis therapeutics market is segmented into metronidazole, paromomycin, tinidazole and other drugs. Metronidazole is expected to dominate the market during the forecast period owing to its high efficacy in treating amebiasis infections. Paromomycin is also anticipated to witness significant growth due to its safety and efficacy profile. Based on application, the global amebiasis therapeutics market is segmented into hospital pharmacies and retail pharmacies.
Product Definition:
Amebiasis Therapeutics is a drug that is used to treat amebiasis, a parasitic infection caused by the protozoan parasite Entamoeba histolytica. Amebiasis can affect the intestines, liver, or other organs. The drug is typically given in combination with other medications. Amebiasis Therapeutics is important because it can help to clear up an infection and improve symptoms.
Metronidazole:
Metronidazole, also known as nitro-imidazole, is an antibiotic used to treat parasitic diseases and bacterial infections. It works by killing the bacteria or parasites in the body. The medicine has a broad spectrum of antimicrobial activity against both gram-positive and negative bacteria.
The drug was first synthesized in 1960s by a Japanese pharmaceutical company named Showa Denko KK; however it was not approved for medical use until 1980s in Japan.
Paromomycin:
Paromomycin is a semi-synthetic antibiotic belonging to the class of drugs known as aminoglycosides. It was first discovered in the 1950s and has been used extensively for treatment against bacterial infections in humans, animals, and plants. The drug has seen extensive research over recent years with scientists continually striving to improve its therapeutic applications.
Application Insights:
Based on the application, the market is segmented into hospital, pharmacy and others. Hospital was estimated as the largest revenue generating segment in 2017 owing to increasing prevalence of chronic diseases such as diabetes and cancer which are associated with Amebiasis. Moreover, rising number of Amebic liver abscess cases has led to an increase in demand for metronidazole drugs from hospitals.
Pharmacy is expected to be fastest growing application over forecast period due to high unmet medical needs especially pertaining metronidazole tablets requirement for treating amebiasis effectively and safely at affordable prices without any adverse effects. Rising incidence rate of amebiasis coupled with high treatment costs is anticipated fuel growth during forecast period thereby driving industry expansion over next eight years ¢â‚¬Å“2030¢â‚¬.
Regional Analysis:
North America dominated the market in 2017 owing to high prevalence of amebiasis and other associated conditions, increasing healthcare expenditure, and rising incidence of drug-resistant forms of the disease. The region is expected to maintain its dominance over the forecast period due to factors such as favorable reimbursement policies for treatment with tinidazole and increasing prevalence of amebiasis.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rise in disposable income, improving healthcare infrastructure & availability along with increase in awareness regarding Amebicare products among patients. Moreover Tinidazole has a wide distribution network across this region which makes it an attractive product for purchase by patients from remote areas resulting into higher sales numbers compared Tinidazole tablets sold within U.S., Canada & Mexico markets (in terms of revenue).
Growth Factors:
- Increasing incidence of amebiasis across the globe
- Rising awareness about amebiasis and its treatment options
- Growing demand for novel and effective therapies for amebiasis
- increasing research and development activities in the field of amebiasis therapeutics
- rising number of collaborations between pharmaceutical companies and research institutes to develop new drugs for treating amebiasis
Scope Of The Report
Report Attributes
Report Details
Report Title
Amebiasis Therapeutics Market Research Report
By Type
Metronidazole, Paromomycin, Tinidazole, Other
By Application
Hospital, Pharmacy
By Companies
Dr. Reddy’s Laboratories, Mission Pharmacal, Aceto Corporation, Mylan Pharmaceuticals, Impax Laboratories, Pfizer, Sanofi, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceutical, Heritage Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Amebiasis Therapeutics Market Report Segments:
The global Amebiasis Therapeutics market is segmented on the basis of:
Types
Metronidazole, Paromomycin, Tinidazole, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy’s Laboratories
- Mission Pharmacal
- Aceto Corporation
- Mylan Pharmaceuticals
- Impax Laboratories
- Pfizer
- Sanofi
- Lupin Pharmaceuticals
- Glenmark Pharmaceuticals
- Sun Pharmaceutical
- Heritage Pharmaceuticals
Highlights of The Amebiasis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Metronidazole
- Paromomycin
- Tinidazole
- Other
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amebiasis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Amebiasis Therapeutics is a biotechnology company focused on the development of novel therapeutics for the treatment of Amebiasis. The company's lead product candidate, AMB-811, is a novel oral anti-amoeba drug that has shown significant efficacy in Phase III clinical trials.
Some of the major companies in the amebiasis therapeutics market are Dr. Reddy’s Laboratories, Mission Pharmacal, Aceto Corporation, Mylan Pharmaceuticals, Impax Laboratories, Pfizer, Sanofi, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceutical, Heritage Pharmaceuticals.
The amebiasis therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amebiasis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Amebiasis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Amebiasis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Amebiasis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Amebiasis Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Amebiasis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Amebiasis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Amebiasis Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Amebiasis Therapeutics Market Size Forecast by Type
5.2.1 Metronidazole
5.2.2 Paromomycin
5.2.3 Tinidazole
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Amebiasis Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Amebiasis Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amebiasis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amebiasis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Amebiasis Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Amebiasis Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Amebiasis Therapeutics Market Size Forecast by Type
9.6.1 Metronidazole
9.6.2 Paromomycin
9.6.3 Tinidazole
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Amebiasis Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Amebiasis Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Amebiasis Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Amebiasis Therapeutics Market Size Forecast by Type
10.6.1 Metronidazole
10.6.2 Paromomycin
10.6.3 Tinidazole
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Amebiasis Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Amebiasis Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Amebiasis Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Amebiasis Therapeutics Market Size Forecast by Type
11.6.1 Metronidazole
11.6.2 Paromomycin
11.6.3 Tinidazole
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Amebiasis Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Amebiasis Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Amebiasis Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Amebiasis Therapeutics Market Size Forecast by Type
12.6.1 Metronidazole
12.6.2 Paromomycin
12.6.3 Tinidazole
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Amebiasis Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Amebiasis Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Amebiasis Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Amebiasis Therapeutics Market Size Forecast by Type
13.6.1 Metronidazole
13.6.2 Paromomycin
13.6.3 Tinidazole
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Amebiasis Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amebiasis Therapeutics Market: Competitive Dashboard
14.2 Global Amebiasis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy’s Laboratories
14.3.2 Mission Pharmacal
14.3.3 Aceto Corporation
14.3.4 Mylan Pharmaceuticals
14.3.5 Impax Laboratories
14.3.6 Pfizer
14.3.7 Sanofi
14.3.8 Lupin Pharmaceuticals
14.3.9 Glenmark Pharmaceuticals
14.3.10 Sun Pharmaceutical
14.3.11 Heritage Pharmaceuticals
